Hologic, Inc. to Post Q2 2025 Earnings of $1.11 Per Share, Zacks Research Forecasts (NASDAQ:HOLX)

Hologic, Inc. (NASDAQ:HOLX) – Research analysts at Zacks Research lifted their Q2 2025 earnings estimates for Hologic in a report released on Wednesday, April 10th. Zacks Research analyst R. Anand now forecasts that the medical equipment provider will post earnings per share of $1.11 for the quarter, up from their previous estimate of $1.10. The consensus estimate for Hologic’s current full-year earnings is $4.02 per share. Zacks Research also issued estimates for Hologic’s FY2025 earnings at $4.28 EPS.

Several other equities analysts also recently issued reports on HOLX. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and boosted their price target for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. Raymond James upped their price objective on shares of Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. UBS Group upped their price target on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. William Blair reissued an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Finally, StockNews.com downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Friday, March 8th. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $87.00.

Hologic Stock Down 3.1 %

Shares of NASDAQ:HOLX opened at $75.11 on Monday. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55. The company has a fifty day simple moving average of $75.66 and a 200 day simple moving average of $72.46. The firm has a market cap of $17.63 billion, a PE ratio of 35.60, a price-to-earnings-growth ratio of 2.62 and a beta of 1.00. Hologic has a 12-month low of $64.02 and a 12-month high of $87.88.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. Hologic’s revenue was down 5.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.07 earnings per share.

Hedge Funds Weigh In On Hologic

Several large investors have recently bought and sold shares of HOLX. McGlone Suttner Wealth Management Inc. bought a new stake in Hologic during the fourth quarter valued at $27,000. Venturi Wealth Management LLC bought a new stake in Hologic during the third quarter valued at $29,000. NBC Securities Inc. bought a new stake in Hologic during the third quarter valued at $33,000. Bartlett & CO. Wealth Management LLC acquired a new position in shares of Hologic during the fourth quarter valued at about $33,000. Finally, Deseret Mutual Benefit Administrators raised its holdings in shares of Hologic by 42.2% during the third quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 155 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Hologic

In related news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Karleen Marie Oberton sold 14,940 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the sale, the chief financial officer now directly owns 103,916 shares in the company, valued at approximately $7,793,700. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the sale, the director now owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,846 shares of company stock worth $2,473,443. Corporate insiders own 1.75% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.